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DIFFERENTIATING BETWEEN HEALTHY CONTROL PARTICIPANTS AND 
THOSE WITH MILD COGNITIVE IMPAIRMENT USING VOLUMETRIC MRI 
DATA 
RENEE DEVIVO 
ABSTRACT 
Objective: To determine whether volumetric measures of the hippocampus or entorhinal 
cortex in combination with other cortical measures can differentiate between cognitively 
normal individuals and participants with amnestic mild cognitive impairment (MCI). 
Methods: T1-weighted magnetic resonance imaging (MRI) data acquired from 46 
cognitively normal participants and 50 participants with amnestic MCI as part of the 
Boston University Alzheimer's Disease Center research registry and the Alzheimer's 
Disease Neuroimaging Initiative were used in this cross-sectional study. Cortical and 
subcortical volumes, including hippocampal subfield volumes, were automatically 
generated from each participant’s structural MRI data using FreeSurfer v6.0. Nominal 
logistic regression models containing these variables were used to evaluate their ability to 
identify participants with MCI. 
Results: A model containing 11 regions of interest (insula, superior parietal cortex, 
rostral middle frontal cortex, middle temporal cortex, pars opercularis, paracentral lobule, 
whole hippocampus, subiculum, superior temporal cortex, precentral cortex and caudal 
anterior cingulate cortex) fit the data best (R2 = 0.7710, whole model test chi square = 
102.4794, p < 0.0001). 
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Conclusions: Volumetric measures acquired from MRI were able to correctly identify 
most healthy control subjects and those with amnestic MCI using measures of selected 
medial temporal lobe structures in combination with those from other cortical areas 
yielding an overall classification of 95.83% for this dataset. These findings support the 
notion that while clinical features of amnestic MCI may reflect medial temporal atrophy, 
differences that can be used to distinguish between these two populations are present 
elsewhere in the brain. This finding further affirming that atrophy can be identified before 
clinical features are expressed. Additional studies are needed to assess how well other 
imaging modalities, such as resting state functional connectivity, diffusion imaging, and 
amyloid and tau position emission tomography (PET), perform in classifying participants 
who are cognitively normal versus those who are amnestic MCI. 
 
  
  vii 
TABLE OF CONTENTS 
 
TITLE……………………………………………………………………………………...i 
COPYRIGHT PAGE……………………………………………………………………...ii 
READER APPROVAL PAGE…………………………………………………………..iii 
ACKNOWLEDGMENTS ................................................................................................ iiv 
ABSTRACT ........................................................................................................................ v 
TABLE OF CONTENTS .................................................................................................. vii 
LIST OF TABLES ............................................................................................................. ix 
LIST OF FIGURES ............................................................................................................ x 
LIST OF ABBREVIATIONS ............................................................................................ xi 
BACKGROUND ................................................................................................................ 1 
Epidemiology ............................................................................................................. 2 
Neuropathology……………..………………………………………………………4 
Symptomology………………………………………………...…………………….5 
INTRODUCTION .............................................................................................................. 8 
METHODS ....................................................................................................................... 11 
Table 1 ...................................................................................................................... 13 
Table 2 ...................................................................................................................... 13 
 
  viii 
RESULTS ......................................................................................................................... 16 
Figure 1 .................................................................................................................... 17 
Figure 2 .................................................................................................................... 18 
Figure 3 .................................................................................................................... 19 
Figure 4 .................................................................................................................... 19 
Table 3 ...................................................................................................................... 21 
DISCUSSION ................................................................................................................... 21 
APPENDIX  ...................................................................................................................... 31 
REFERENCES ................................................................................................................. 34 
CURRICULUM VITAE ................................................................................................... 39 
 
  
  ix 
LIST OF TABLES 
 
Table Title Page 
1 Demographic Data of Control and MCI Groups 13 
2 Neuropsychological Test Performance of Control and 
MCI Groups 
13 
3 ROI Predictors of Group Membership 21 
 
  
  x 
LIST OF FIGURES 
 
Figure Title Page 
1 Mean Volume of Left Uncorrected Hippocampal 
Subfields 
17 
2 Mean Volume of Right Uncorrected Hippocampal 
Subfields 
18 
3 Mean Volume of Uncorrected Entorhinal Cortices 19 
4 Mean Volume of Uncorrected Whole Hippocampal 
Formations 
19 
  
  xi 
LIST OF ABBREVIATIONS 
Aβ  ................................................................................................................... Amyloid-Beta 
AD ........................................................................................................ Alzheimer’s Disease 
ADC  ......................................................................................... Alzheimer’s Disease Center 
ADNI............................................................. Alzheimer’s Disease Neuroimaging Initiative 
ANCOVA .......................................................................................... Analysis of Covariate 
APOE ......................................................................................................... Apolipoprotein E 
BU ............................................................................................................ Boston University 
CA ............................................................................................................... Cornu Ammonis 
CDR ............................................................................................... Clinical Dementia Score 
CSF ........................................................................................................ Cerebrospinal Fluid 
DICOM ................................................. Digital Imaging and Communications in Medicine 
eTIV ............................................................................ Estimated Total Intracranial Volume 
FDR…………………………………………………………………..False Discovery Rate 
FOV................................................................................................................. Field of View 
GDS............................................................................................. Geriatric Depression Scale 
HOPE ................................................................... Health Outreach Program for the Elderly 
IRB ............................................................................................. Institutional Review Board 
MCI……………………………………………………………Mild Cognitive Impairment 
MM ..................................................................................................................... Millimeters 
MMSE ............................................................................... Mini Mental Status Examination 
MPRAGE ............................. Magnetization-Prepared Rapid Acquisition of Gradient Echo  
  xii 
MRI ........................................................................................ Magnetic Resonance Imaging 
MS ..................................................................................................................... Milliseconds 
NACC ............................................................... National Alzheimer’s Coordinating Center 
NIA ............................................................................................ National Institute on Aging 
PET ..................................................................................... Position Emission Tomography 
ROI ............................................................................................................ Region of Interest 
T .................................................................................................................................... Tesla 
TBI ................................................................................................... Traumatic Brain Injury 
TE  ........................................................................................................................ Echo Time 
TR ............................................................................................................... Repetition Time 
WMS-R ....................................................... Wechsler D. Wechsler Memory Scale-Revised 
 
  1 
BACKGROUND 
 In 2017, approximately 5.5 million people in the United States were living 
with a diagnosis of Alzheimer’s disease (AD). This means that roughly 1 in 10 persons 
above 65 years of age had been diagnosed with AD while perhaps an equal number are 
now playing the role as primary caregiver for a spouse with AD. The risk of AD 
increases with age as currently 3% of people between ages 65-74 have been diagnosed 
with AD, 17% of people between ages 75-84 have been diagnosed with AD, and 32% of 
people over 85 have been diagnosed with AD (Alzheimer’s Association, 2017). Given 
that the first members of the baby boomer generation turned 70 in 2016, the number of 
adults 65 and older in America is expected to nearly double by the year 2020 and thus, 
the incidence of AD and other forms of dementia will likely grow as well. The 
Alzheimer’s Association (2017) estimates by the year 2025, roughly 7.1 million 
Americans 65 and older will have some form of dementia.  
In addition to the growing proportion of the population diagnosed with dementia, 
another 15-20% of people age 65 and older have been diagnosed with mild cognitive 
impairment (MCI) (Alzheimer’s Association, 2017). People who have MCI are thought 
to suffer mild, yet measurable changes in their cognitive function that are noticeable to 
the person affected and often to close friends and family, but not to an extent that fully 
disrupts daily life. However, people with MCI are more likely to develop AD dementia, 
and it is estimated that in any given year 15% of all individuals with MCI will progress to 
AD (Davatzikos et al., 2012). As a result, much research in recent years has focused upon 
this population in hopes to better identify biomarkers and ultimately treatments for people 
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suffering from the earliest effects of AD. Such information is critical for accuracy of 
diagnosis and family/caregiving planning, as well as for future medical intervention and 
treatment.  
Epidemiology 
In recent years, researchers have put forth a great deal of effort in identifying risk 
factors for AD with mixed results. At this time, the largest risk factors are thought to be 
age, family history, and the presence of apoliprotein E (APOE) 4 (Alzheimer’s 
Association, 2017). As described in the previous section, the incidence of AD is known 
to increase with age making older adults more suspectible. In regards to the other two 
factors, neither is required to develop AD, but having either a family history of AD or a 
copy of the APOE 4 gene is known to increase the lifetime risk for developing AD. In 
terms of family history, people with a sibling or parent with AD (i.e. first degree relative) 
are more likely to develop the disease, and people with one or more first-degree relatives 
with AD are at an even higher risk (Alzheimer’s Association, 2017). The APOE gene has 
received much attention in recent years as scientists speculate whether certain 
combinations of the gene can actually increase or decrease one’s risk of AD. Everyone 
inherits a copy of the gene, in forms 2, 3, or 4, from each parent. At this time, 
researchers believe the 4 copy increases one’s lifetime risk of developing AD and those 
with two copies of 4 are at an even higher risk (Reitz & Mayeux, 2014). Additionally, it 
is thought that people who have 4 copies may progress from MCI to AD in a shorter 
time frame and show signs of cognitive decline faster than those who do not (Aisen et al., 
  3 
2017). Conversely, people with copies of the 2 gene seem to have a lowered lifetime 
risk though this finding continues to be explored (Alzheimer’s Association, 2017).   
 Other modifiable risk factors for AD are lifestyle factors. It is thought that 
maintaining a healthy body weight, good cerebrovascular health, a healthy diet, and 
engaging in both physical and intellectual activity throughout one’s lifetime are helpful 
measures that may reduce one’s risk of developing AD (Aisen et al., 2017). Other factors 
like smoking, having above average blood pressure between the ages of 40-60, 
developing type 2 diabetes or other metabolic syndromes, or suffering a traumatic brain 
injury (TBI) may increase the likelihood of AD in one’s lifetime (Reitz & Mayeux, 
2014).  
 At this time, most suggested treatment methods for AD fall into two categories: 
pharmacologic therapies and non-pharmacologic therapies. Unfortunately, the 
pharmacologic treatments available at this time are symptom modifying, but unable to 
stop or slow the neuronal damage that occurs in AD. The six drugs currently marketed for 
AD serve to increase the lifespan of the neurotransmitter, acetylcholine, in the brain by 
reducing the action of the compound (acetylcholinesterase) designed to stop the 
neurotransmitter’s action.  Sadly, the effectiveness of such medications has been variable 
per individual and is limited in the amount of time that it remains effective (Alzheimer’s 
Association, 2017). Similar to its’ pharmacologic alternatives, no direct links have been 
found between non-pharmacologic therapies and decreasing the risk or severity of AD, 
but many research studies have found activities such as exercise and cognitive 
stimulation prove beneficial for those exhibiting symptoms of AD.  
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Neuropathology 
Interestingly, some of the first neuropathological changes in the brain are thought 
to occur roughly 15 years before the overt onset of cognitive impairment (Alzheimer’s 
Association, 2017; see review Aisen et al., 2017). The two most prominent features that 
characterize AD dementia are amyloid-beta (Aβ) plaques and neurofibrillary tangles. 
Generally, it is believed that changes in Aβ deposition occur first and are followed by the 
build-up of tau pathology resulting in subsequent neurodegeneration over time. 
Neurodegeneration and atrophy of the affected regions is thought to occur due to the 
presence of both Aβ plaques and neurofibrillary tangles that disrupt synaptic structures 
and cause neurons to die (Aisen et al., 2017; Spires-Jones & Hyman, 2014).  It should be 
noted that the presence of Aβ plaques and neurofibrillary tangles alone is not proof of AD 
as many cognitively normal adults also have the formation of Aβ plaques in their brain as 
they age despite the absence of dementia (Aisen et al., 2017; Gomez-Isla et al., 1996).  
Studies conducted in the past 20-30 years have attempted to further investigate the 
distribution pattern of how Aβ plaques and neurofibrillary tangles spread throughout the 
brain (Braak & Braak, 1991). Amyloid deposits are thought to first appear in basal 
portions of the cortex, before spreading into various cortical association areas with 
limited involvement of the hippocampus, then lastly into the motor and sensory cortices 
(Braak & Braak, 1991). As these Aβ deposits accumulate, they form aggregates termed 
“plaque-like” structures.  The neurofibrillary changes that follow Aβ plaque formation 
are thought to start in the locus coeruleus and then spread to the transentorhinal region, 
referred to as stages I-II, before spreading further to the limbic regions (stages III-IV) and 
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lastly into cortical regions (stages V-VI) (Braak & Braak, 1991). The hippocampus and 
entorhinal cortex are primarily effected in stages III-IV, but initial changes may begin to 
occur as early as stages I-II. Specifically, the CA1 subfield of the hippocampus is thought 
to show the earliest changes. Motor regions of the brain remain spared until relatively late 
in the disease (Pini et al., 2016). Given that Aβ deposits are believed to occur in the 
earliest phases of the continuum, many researchers believe it is the presence of 
neurofibrillary tangles that are more directly correlated to symptoms of cognitive decline 
(Aisen et al., 2017). Specifically, tau deposits in the entorhinal cortex often involve layer 
II and cause a disruption between this region of the neocortex and the hippocampus. This 
disconnection hinders the transfer of information from the cortex to the hippocampus and 
is thought to clinically manifest as episodic memory deficits (Pini et al., 2016). In years 
to come, it can be expected that biomarkers, such as Aβ plaques and neurofibrillary 
tangles, will continue to be highly studied with measures such as magnetic resonance 
imaging (MRI), cerebrospinal fluid (CSF), and amyloid beta and tau position emission 
tomography (PET) as all forms allow good visibility of brain structures and tissues 
without being overly invasive. At the same time, it is expected scientists will continue to 
use these forms of imaging in hopes of detecting other telling biomarkers that have not 
yet have been discovered (Alzheimer’s Association, 2017). 
Symptomology  
 Reasons the treatment and prevention of AD remains so elusive to researchers are 
because (1) there is no single diagnostic test for AD, (2) the way it presents in individuals 
differs widely and with a variable time frame and (3) irreversible damage may be present 
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in the brain by the time the clinical symptoms of AD manifest. The process of diagnosing 
AD is a lengthy one as it involves a thorough medical and family history, 
neuropsychological assessment of all cognitive domains, blood tests and imaging, as well 
as help from a close family member or friend who is able to provide insight about the 
individual’s daily life and behaviors. This extensive information is needed because the 
clinical diagnosis of AD is based more on exclusionary criteria than inclusionary ones. 
Thus, there needs to be an impairment of memory as well as an impairment in another 
cognitive domain (i.e. executive function, attention, language or visuospatial abilities) 
with no other medical reason for these impairments. Once someone is diagnosed with 
AD, the time frame in which symptoms escalate can greatly vary depending on the 
severity of the disease, confounding health factors, age, education, and overall 
intelligence as some individuals are able to mask symptoms for longer periods of time 
and maintain seemingly normal daily functioning (Alzheimer’s Association, 2017; see 
review Aisen et al., 2017).  
As mentioned, the initial symptoms of AD often vary per individual, but are 
usually characterized by problems with episodic memory and a rapid rate of forgetting 
(Alzheimer’s Association, 2017; National Institute on Aging, 2017). While some age-
related changes in memory are to be expected and even considered a “normal” part of the 
aging process, changes in memory become a problem when they begin to effect daily life 
and it is these types of changes that are associated with AD. Such changes include 
forgetting recently learned information, having to ask for the same information 
repeatedly, relying on others for memory, or having to write down excessive notes in 
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order to remember something. Cognitive changes can also be reflected in language, 
speaking, writing, or completing tasks as people have difficulty finding the “right” word, 
or struggle to explain the sequence of instructions necessary to complete a task.  
Other non-memory impairments can be seen in visuospatial orientation or 
impaired reasoning and judgement (Alzheimer’s Association, 2017). People in early 
stages of AD often have trouble orienting themselves to less familiar places, confusion 
regarding time or place, or difficulty gauging distances and other visual problems. 
Additional trouble with problem solving, impaired reasoning, and judgement can be 
reflected in poor concentration, tasks taking longer to perform, difficulty handling 
money, or poor decision making (Alzheimer’s Association, 2017).  
As the disease progresses, these symptoms are magnified and accompanied by 
more outward social and personality changes (National Institute on Aging, 2017). People 
suffering moderate AD often become more withdrawn in social situations, have increased 
anxiety and aggression, and are more prone to irritability and depression. New 
compulsive or repetitive behaviors may be noticed as well. Memory loss at this time also 
worsens, and begins to include more autobiographical facts about one’s own life instead 
of forgetting more trivial information recently learned. The last and final symptoms to 
present are the most devastating as many are not compatible with life. In the very late 
stages of AD, people often require around-the-clock care as they can no longer take care 
of themselves. Often times, people in the most severe stages of AD eventually lose the 
ability to communicate with others and their bodies lose the ability to fight viruses, 
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perform physical movement, and even swallow -- all of which can ultimately lead to 
death (National Institute on Aging, 2017). 
INTRODUCTION 
The overall prevalence of AD continues to rise as the average human life span 
grows and thus the global population is aging. In recent years, researchers have come to 
view AD as a continuum, rather than a sequence of distinct phases of cognitive and 
neuropathological changes (Aisen et al., 2017). The earliest parts of the continuum are 
referred to as “preclinical” and individuals are characterized as cognitively asymptomatic 
regardless of having AD pathology. However, it is recognized many “preclinical” 
individuals may progress to a symptomatic presentation, and when symptoms, such as 
episodic memory loss and other cognitive dysfunction, become apparent, this phase is 
referred to as MCI. In recent years, MCI has been clinically characterized by criteria such 
as: self- or informant-reported cognitive complaints, objective cognitive impairment, 
preserved independence in functional abilities, and the absence of dementia (Petersen et 
al., 2014). As the disease continues to progress, cognitive impairment worsens and 
functional impairment becomes increasingly apparent in everyday life, and at this point, a 
person is considered to have AD dementia (Aisen et al., 2017). Thus, with this growing 
understanding of AD as a continuum, the need to identify biomarkers indicative of the 
pathophysiological changes that occur prior to cognitive and functional impairment is 
crucial to develop better diagnostic and treatment techniques. 
Morphometric MRI studies have established that the areas of the brain often first 
damaged in MCI and AD dementia are the hippocampus and the entorhinal cortex (Du et 
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al., 2001; Killiany et al., 2000; see reviews Pini et al., 2016; Zhou et al., 2016). Aside 
from their roles in memory, these regions are thought to be some of the first areas to 
show the impact of aging (Thaker et al., 2017). Amyloid beta (Aβ) accumulates and 
forms plaques outside of nerve cells, while tau proteins aggregate within neurons and 
form neurofibrillary tangles that are thought to cause neuronal death and reduced volume 
in affected regions (Gomez-Isla et al., 1996; see review Spires-Jones & Hyman, 2014).  
In an effort to obtain more sensitive and specific measures of medial temporal lobe 
structures, researchers who use structural MRI are encouraging the segmentation of the 
hippocampus into subfields (De Flores, LaJoie, & Chetelat, 2015, Pini et al., 2016). 
To date, numerous studies have found reductions in the volumes of the whole 
hippocampus, hippocampal subfields, and entorhinal cortex in the brains of MCI and AD 
patients when compared to control subjects (Mueller et al., 2010; Pennanen et al., 2004; 
see review De Flores et al., 2015). Such studies often utilize a cross-sectional approach in 
which they identify previously diagnosed subjects as controls, MCI, or AD based solely 
upon the characteristics of various regions of interest (ROIs) (Colliot et al., 2008; Du et 
al., 2001; Hanseeuw et al., 2011; Khan et al., 2015; Mueller et al., 2010, Xu et al., 2000). 
However, it should be noted that many of these studies largely focus on subjects who 
already have MCI in order to best predict who with MCI will convert to AD, (Khan et al., 
2015; Killiany et al., 2000; Plant et al., 2010; Westman et al., 2011) with less emphasis 
on creating fit models that can accurately discriminate between control subjects and MCI. 
Those that do examine these two populations often use the characteristics of only one 
ROI as a predictor variable, such as the hippocampus, entorhinal cortex, or a specified 
  10 
hippocampal subfield, and have classification rates that rarely exceed 80% (Colliot et al., 
2008; Du et al., 2001; Hanseeuw et al., 2011; Mueller et al., 2010; Pennanen et al., 2004; 
Westman et al., 2011, see review Weiner et al., 2015). Thus, there remains significant 
room for models that can predict classification of subjects in earlier stages of the AD 
continuum with greater accuracy, and for further exploration of regions implicated 
outside of the hippocampus and entorhinal cortex.  
The goal of the present study was to utilize volumetric MRI measures to identify a 
broader set of variables that would better distinguish controls and amnestic MCI 
participants using logistic regression. The first step was to systematically determine the 
utility of using the whole hippocampus, hippocampal subfields, and entorhinal cortex as 
predictors. Next, less-studied cortical regions outside the medial temporal lobe were 
added to the model to determine whether any of these regions could improve the model 
fit and classification accuracy. While these regions are not as commonly used in 
classification models, researchers have been finding more consistent patterns of atrophy 
in MCI and AD subjects in surrounding regions of the medial temporal lobe including the 
frontal, parietal, and temporal lobes (Hangii et al., 2011). Knowledge regarding the 
discriminatory value of these regions in cognitively normal subjects and those with MCI 
could serve as valuable information to aid the diagnostic process of MCI and AD 
dementia at an earlier time point as well as focus treatment therapies. 
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METHODS  
Participants 
This study utilized the MRI scans of 96 subjects selected from two sources. Data 
from 42 subjects were obtained from the Boston University Alzheimer’s Disease Center 
(BU ADC) Clinical Core Registry. The BU ADC is one of 30 centers funded by the 
National Institute on Aging (NIA) that contributes data to the National Alzheimer’s 
Coordinating Center (NACC). The BU ADC registry, including participant recruitment 
and inclusion/exclusion criteria, has been described elsewhere (e.g., Ashendorf et al. 
2017; Galetta et al., 2017). Subjects’ diagnoses were made at multidisciplinary consensus 
conferences, following presentation and discussion of all history and evaluation results. 
Subjects were determined to have normal cognition (n=19) if their objective 
neuropsychological test scores were within the normal range, they had a Clinical 
Dementia Rating (CDR; Morris, 1993) Global Score of 0.0, and were determined by the 
consensus panel to be cognitively normal. MCI diagnoses (n=23) followed criteria 
outlined by Petersen and colleagues (2014). All 23 MCI subjects included in this study 
were amnestic MCI. Of the 23 MCI subjects, 15 had decreased abilities in one cognitive 
domain (memory) and 8 were affected in one or more cognitive domains.  
Data from the remaining 54 subjects were obtained from the Alzheimer’s Disease 
Neuroimaging Initiative (ADNI) database (for more information, refer to 
adni.loni.usc.edu). The ADNI was launched in 2003 as a public-private partnership, led 
by Principle Investigator, Michael W. Weiner MD. The primary goal of the ADNI has 
been to elucidate clinical, genetic, imaging, and biochemical biomarkers of AD and to 
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better understand the progression from normal cognition to MCI to AD (Weiner et al., 
2015). Twenty-seven of these subjects were cognitively normal controls and the other 27 
subjects were individuals with amnestic MCI in a single domain. ADNI participants were 
selected based on utility of a Philips 3T Scanner (to ensure comparable imaging 
parameters used to collect data from HOPE participants) and criteria that would properly 
balance the demographic data of the HOPE participants. Procedures conducted in both 
HOPE and ADNI were approved by local IRBs and participants gave informed consent at 
the time of their enrollment in both studies. 
The study was comprised of 42 males and 54 females. Both HOPE and ADNI 
collect demographic data including age, education and APOE 4 status as well as 
neuropsychological test scores from the Mini-Mental State Exam (MMSE), Geriatric 
Depression Scale (GDS), Logical Memory recall (modified from the Wechsler D. 
Wechsler Memory Scale-Revised (WMS-R) San Antonio, Texas: Psychological 
Corporation; 1987), and Part B of the Trailmaking Test. This data was collected from all 
participants (Tables 1 and 2).  
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Table 1. Demographic Data of Control and MCI Groups 
p value < 0.01, MCI = Mild Cognitive Impairment, APOE = Apolipoprotein E  
 
Table 2. Neuropsychological Test Performance of Control and MCI Groups 
p value < 0.01, MCI = Mild Cognitive Impairment, MMSE = Mini Mental State Examination, 
GDS = Geriatric Depression Scale 
 
 
 
Mean Control Raw 
Score ± Standard 
Deviation 
 
Mean MCI Raw 
Score ± Standard 
Deviation 
 
p value (* 
denotes 
significance) 
 
Logical Memory 
Immediate (n = 87) 
 
15.79 (2.97) 
 
10.82 (4.71) 
 
3.99 x E-08* 
 
Logical Memory Delayed      
(n = 87) 
 
14.86 (3.41) 
 
9.25 (5.04) 
 
1.70 x E-08* 
 
MMSE (n = 96) 
 
29.27 (0.96) 
 
28.00 (1.99) 
 
9.76 x E-05* 
 
GDS (n = 95) 
 
0.78 (1.06) 
 
1.56 (2.45) 
 
0.025 
 
Part B of Trailmaking 
Test (n = 96, Time to 
completion in seconds) 
 
70.48 (21.05) 
 
130.24 (82.88) 
 
3.64 x E-06* 
 
 
 
(n = 96) 
 
Means for Control 
Group ± Standard 
Deviation 
 
Means for MCI 
Group ± Standard 
Deviation 
 
p value (* 
denotes 
significance) 
 
Age (in years) 
 
75.24 (8.50) 
 
74.48(6.76) 
 
0.63 
 
Education (in 
years) 
 
16.02 (2.44) 
 
16.56 (2.57) 
 
0.3 
 
APOE 4 Status 
(n=94) 
 
37.78% of Controls have 
at least 1 4 allele 
 
32.65% of MCI have 
at least 1 4 allele 
 
0.87 
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Imaging Assessments 
In this study, we used the 3D magnetization-prepared rapid acquisition of gradient 
echo (MPRAGE) sequence scans from all subjects.  These scans were acquired on 3T 
Philips scanners.  For the BU ADC scans, a 32-channel headcoil and sense factor of 2 
was used with the following imaging parameters: TR = 6.7 ms, TE = 3.1 ms, flip angle = 
9°, reconstructed and acquisition voxel size = 0.98 x 0.98 x 1.2 mm, FOV = 250 mm x 
250 mm x 180 mm, 150 sagittal slices. Full details of the MRI acquisition parameters 
used in ADNI have been discussed elsewhere (Jack et al., 2008). All ADNI scans utilized 
for this study were acquired with an 8-channel headcoil and a sense factor of 1.8 with the 
following imaging parameters: TR = 6.8 ms, TE= 3.1 ms, flip angle = 9°, reconstructed 
voxel size = 1.05 mm x 1.05 mm x 1.20 mm, acquisition voxel size = 1.11mm x 1.11mm 
x 1.20mm, FOV = 270mm x 252 mm x 240 mm, 170 sagittal slices. DICOM scans were 
downloaded from the ADNI database. 
The MRI data from both databases were automatically segmented with Freesurfer 
v6.0 (http://surfer.nmr.mgh.harvard.edu; for additional details see Desikan et al., 2006; 
Iglesias et al., 2015). Freesurfer v6.0 utilizes an improved atlas that can automatically 
segment hippocampal regions into a greater number of subfields than previous versions 
have allowed (Iglesias et al., 2015). 
Statistical Analysis 
Independent samples t tests were used to assess whether significant differences 
existed between the control and MCI groups in terms of demographic factors, 
neuropsychological outcome measures, and MRI outcome measures. A chi square test 
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was performed to determine whether there were any significant differences in APOE 4 
status between the groups. To control for the number of comparisons, a Bonferroni 
corrective value of p = 0.01 was used.  Volumes generated from Freesurfer v6.0 included 
estimated total intracranial volume (eTIV), third and fourth ventricle volume, 68 cortical 
volumes (34 from each hemisphere), 12 subcortical volumes (6 from each hemisphere), 
the right and left hippocampal volumes, 24 hippocampal subfields (12 in each 
hemisphere; for additional segmentation details see Iglesias et al., 2015). For a complete 
list of the variables collected from FreeSurfer v6.0, see Appendix. A subset of the data 
was visually inspected for errors and upon finding no significant errors, cortical surfaces 
were not edited. An ANCOVA was performed on the data to determine whether factors 
such as eTIV, age, gender, education, APOE 4 status, or study (i.e. HOPE or ADNI) had 
a significant effect on any volumetric MRI variables. Age and eTIV had a significant 
effect on majority of the ROI volumes, while gender, education, APOE 4, and study had 
no significant impact. In order to correct for age and eTIV, residuals were computed 
based on the control population data for each of the ROI volumes.   
Using these residuals, separate nominal logistic regression models were created to 
determine how well the volumes of individual regions such as the entorhinal cortex, 
whole hippocampus, and hippocampal subfields could identify group membership. 
Subsequently, stepwise variable logistical models (mixed, probability to enter p < 0.25) 
were run using subgroups of ROIs (subcortical, cortical, and hippocampal subfields) to 
see which ROIs classified participants best. Whole hippocampal formation was included 
with the subfields and the entorhinal cortex was included with the cortical regions. A 
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final nominal logistic regression model using a compilation of the significant volumetric 
MRI variables from all three stepwise analyses was created in order to create an optimal 
classification model of group membership. Following this analysis, a leave-one-out 
prediction of the one-out validation technique was conducted to verify the model was 
transferrable to another data set (Fan et al., 2008; Misra et al., 2009). 
RESULTS 
Demographic Data 
Tables 1 and 2 show the demographic and cognitive data from the control and 
MCI groups. There were no significant differences between the groups in terms of age, 
years of education, or APOE 4 status (p’s > 0.01). As expected, significant differences 
were found between the control and MCI groups for MMSE score, Logical Memory 
Immediate Raw Score, Logical Memory Delayed Raw Score, and Part B of the 
Trailmaking Test (p’s < 0.01). There was a trend for the MCI participants to have higher 
GDS scores (p = 0.025) though neither group expressed clinically relevant scores on the 
GDS.  
MRI Data 
Significant differences (p’s < 0.01) observed in uncorrected ROI volumes are 
illustrated in Figures 1-4. When comparing uncorrected volumes, the MCI group had 
smaller volumes in 15 of the 24 hippocampal subfields, the right and left whole 
hippocampal formations, and the right entorhinal cortex, when compared to the control 
group. In comparing the residual data between the control and MCI groups, the same 
15/24 hippocampal subfields, both hippocampal formations, and the right entorhinal 
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cortex remained significantly smaller with the addition of three additional hippocampal 
subfields (left fimbria, right hippocampal tail, and right fimbria) and the left entorhinal 
cortex. 
Figure 1. Mean Volume of Left Uncorrected Hippocampal Subfields  
 
 
 
 
The mean volume of 12 identified hippocampal subfields was measured in control and MCI subjects. 
Regions showing significant differences (p < 0.01) are denoted with a (*) and can be seen in 8 of the 12 
subfields of the left hippocampus where the MCI subjects had reduced volume in comparison to the control 
subjects. Error bars represent standard error of the mean. MCI = Mild Cognitive Impairment, CA = Cornu 
Ammonis 
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Figure 2. Mean Volume of Right Uncorrected Hippocampal Subfields 
 
 
 
 
The mean volume of 12 identified hippocampal subfields was measured in control and MCI subjects. 
Regions showing significant differences (p < 0.01) are denoted with a (*) and can be seen in 7 of the 12 
subfields of the right hippocampus where MCI subjects had reduced volume in comparison to the control 
subjects. Error bars represent standard error of the mean. MCI = Mild Cognitive Impairment, CA = Cornu 
Ammonis 
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Figure 3. Mean Volume of Uncorrected Entorhinal Cortices 
 
 
 
 
The mean volume of the right and left entorhinal cortices were measured in control and MCI subjects. The 
right entorhinal cortex in MCI subjects showed a significant reduction in volume compared to control 
subjects and this loss is indicated by a (*) (p < 0.01). Error bars represent standard error of the mean. MCI 
= Mild Cognitive Impairment 
 
Figure 4. Mean Volume of Uncorrected Whole Hippocampal Formations 
 
 
The mean volume of the right and left hippocampal formations were measured in control and MCI subjects. 
Both right and left hippocampal formations in MCI subjects showed a significant reduction in volume 
compared to control subjects and this loss is indicated by a (*) (p < 0.01). Error bars represent standard 
error of the mean. MCI = Mild Cognitive Impairment 
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To determine how well the volumes of the entorhinal cortex, hippocampus, and 
hippocampal subfield identified group membership, these variables were entered into 
three separate nominal logistic regression models consisting of both the right and left 
volumes of each region.  Though some were significant, none of these models provided a 
good model fit according to the R2 values obtained: hippocampal subfields (R2 = 0.3629, 
whole model test chi square = 48.2361, p = 0.0024), whole hippocampus (R2 = 0.1817, 
whole model test chi square = 24.1557, p < 0.0001), and entorhinal cortex (R2 = 0.0688, 
whole model test chi square = 9.1421, p = 0.0103). Thus, subgroup ROI stepwise variable 
models were conducted. ROIs that were significant in these stepwise variable models (p’s 
<0.01 FDR corrected) were entered into a final nominal logistic regression model which 
showed that 11 variables were significant (R2 = 0.7710, whole model test chi square = 
102.4794, p < 0.0001) (Table 3). This model had an overall classification rate of 0.9583 
(misclassification rate = 0.0417) as 44 out of 46 control participants and 48 out of 50 
MCI participants were classified correctly. Surprisingly, entorhinal volume was not one 
of the factors selected into the final nominal logistic model and when forced into the final 
model, it did not have a significant effect and was ultimately excluded. Additionally, a 
leave-one-out prediction of the one-out validation technique was conducted and reached 
an average classification rate of 0.7742 and drew upon the same top five predictor 
variables as the original model (Table 3). 
 
 
 
  21 
Table 3. ROI Predictors of Group Membership 
Significant differences (p < 0.01) are denoted with a (*). CA = Cornu Ammonis. 
 
 
DISCUSSION 
Demographics  
In this study, the groups were well matched in terms of their demographics (i.e. 
age, education, APOE ε4 status, and gender) (Table 1). Neuropsychological measures 
revealed expected differences between the control and MCI groups. For example, the 
control group performed better than the MCI group on four of the five 
neuropsychological tasks assessed (Logical Memory Immediate Recall, Logical Memory 
 
 
Region FDR P Value Effect Likelihood Ratio Test 
(* denotes significance) 
Left Insula 0.0003* 
Left Superior Parietal Cortex 0.0003* 
Left Rostral Middle Frontal Cortex 0.00039* 
Right Middle Temporal Cortex 0.00059* 
Right Pars Opercularis 0.00059* 
Right Paracentral Lobule 0.00086* 
Left Whole Hippocampus 0.00281* 
Right Subiculum 0.00281* 
Left Superior Temporal Cortex 0.00281* 
Right Precentral Cortex 0.00281* 
Right Caudal Anterior Cingulate Cortex 0.00281* 
Left Putamen 0.01446 
Right Pericalcarine Cortex 0.02955 
Left Fusiform Cortex 0.04350 
Right Parasubiculum 0.10144 
Left Hippocampal Amygdala Transition 
Area 
0.14714 
Right Thalamus Proper 0.15060 
Right CA3 0.18569 
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Delayed Recall, MMSE, and Part B of the Trailmaking Test) (Table 2).  A difference in 
GDS score approached significance (p = 0.025) with the MCI group endorsing, on 
average, 0.75 points higher on this scale. It is feasible this difference is a result of the 
GDS specifically asking about a decrease in memory, rather than a reflection of true 
depression symptoms. 
MRI  
In this study, we found smaller volumes in almost all of the residual ROI volumes 
examined in the MCI group compared to the control group. Specifically, smaller residual 
volumes were found in the MCI group in 18 of the 24 hippocampal subfields, bilateral 
hippocampal formations, and the bilateral entorhinal cortices. These findings are 
consistent with other reports in the literature (Hanseeuw et al., 2011; La Joie et al., 2013; 
Du et al., 2001; Killiany et al., 2000; Pennanen et al., 2004; see review Zhou et al., 2016).  
Hippocampal Subfields  
In recent years, attention has shifted from examining whole hippocampal volume 
to examining the volume of specific hippocampal subfields. Proponents of this shift have 
argued that since hippocampal subfields are smaller, functionally distinct, and differ in 
neuroplasticity, they may better differentiate normal aging and the presence of age-
related disease (La Joie et al., 2013; Mueller et al., 2010; see review Pini et al., 2016). In 
terms of the progression of Alzheimer’s disease, neurofibrillary tangles in the medial 
temporal region are initially found in the CA1 region and later are found in the 
subiculum, CA2, CA3, then the CA4 and dentate gyrus (De Flores et al., 2015; Pini et al., 
2016).  
  23 
Numerous studies have confirmed that MCI subjects have smaller volumes in the 
CA1 when compared to controls (La Joie et al., 2013; Mueller et al., 2010; see review De 
Flores et al., 2015). Further evidence of the CA1 being closely related to memory 
dysfunction was noted in the case of R.B, a famous neurological patient who suffered 
from several episodes of ischemia that led to pronounced memory deficits as a result of 
lesions primarily in the CA1 region of the hippocampus (Zola-Morgan, Squire, & 
Amaral, 1986). Notably, the present study also found significantly smaller residual 
volume in the bilateral CA1 subfields in individuals with MCI when compared to control 
subjects. Likewise, a study done by Khan and colleagues (2015) confirmed smaller 
volume in the bilateral CA1 subfields as well as the bilateral subiculum and presubiculum 
in stable MCI subjects when compared to controls. Volume reduction in the subiculum 
and presubiculum is becoming more widely recognized in MCI while volume loss in the 
CA2, CA3, and the dentate gyrus is not as consistently observed in MCI (Khan et al., 
2015; Li et al., 2016). In the present study, significantly smaller residual volume was 
found bilaterally in the subiculum, CA3, and dentate gyrus along with other less-studied 
subfields of the hippocampus (Figures 1 and 2). More longitudinal research is needed on 
subfields in order to determine the timing of neuropsychological and neuropathological 
changes in relation to disease progression (De Flores et al., 2015; Pini et al., 2016). 
Entorhinal Cortex 
Histological studies in the 1990’s established that neurofibrillary tangles likely 
first appear in the entorhinal cortex before progressing to other areas of the medial 
temporal lobe (Gomez-Isla et al., 1996). These studies suggest the entorhinal cortex is 
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one of the first regions to experience pathological changes in the progression of cognitive 
impairment in AD (Pini et al., 2016; Zhou et al., 2016). Several studies have since found 
smaller entorhinal cortex volumes exist in AD subjects compared to controls, and more 
recent studies are confirming smaller entorhinal volume in MCI subjects compared to 
controls (Pennanen et al., 2004). Less work has been done analyzing whether the left or 
right entorhinal cortex is more suspectible to atrophy, but in studies analyzing both 
healthy young and elderly adults, the right entorhinal cortex has been found to be larger 
than the left in both populations (De Toledo-Morrell et al., 2000; Insauti et al., 1998). The 
study conducted by De Toledo-Morrell and colleagues (2000) also found solely the right 
entorhinal cortex was significantly reduced in volume in elderly subjects when compared 
to younger adults. Both these observations have led some researchers to believe the right 
entorhinal cortex may be more vulnerable to aging and atrophy than the left (Zhou et al., 
2016). The present study also found significant differences in the residual data of both the 
left and right entorhinal cortices of the control group in comparison to the MCI group.  
Whole Hippocampus 
Researchers heavily study the hippocampus due to its known role in episodic 
memory, decreases in which are a hallmark sign of cognitive impairment (Mueller et al., 
2010; Slavin et al., 2007). It has been established that even in older healthy adults, 
hippocampal volume decreases with age, making it a region that is susceptible to atrophy 
(Driscoll et al., 2009; Raz et al., 2004). As with the entorhinal cortex, some debate 
remains as to whether one hemisphere is more vulnerable than the other, or if both are 
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equally vulnerable. A study by Slavin and colleagues (2007) found significant decreases 
in only the left hippocampal formation of amnestic MCI participants in comparison to 
controls. Other studies, including this one, have found no significant differences between 
the volumes of the right and left hippocampi (Elshafey et al., 2014), but that the residual 
volumes of both regions are significantly smaller in MCI subjects when compared to 
healthy controls (Du et al., 2001; Pluta et al., 2012; Shi et al., 2009). 
Nominal Logistic Model of Group Membership 
The present study sought to expand current knowledge regarding what regions of 
the brain are most influential in classifying those who are cognitively normal versus those 
with amnestic MCI. Some studies have reported the entorhinal cortex to be most effective 
at discriminating between controls and subjects with cognitive impairment (Killiany et 
al., 2001; Pennanen et al., 2004). Yet, others have found the entire hippocampal 
formation or various hippocampal subfield volumes to perform best (Du et al., 2001; 
Hanseeuw et al., 2011; Mueller et al., 2010; Xu et al., 2000). Regardless, a majority of 
cross-sectional studies attempting to build similar classification models utilize only one 
region to classify individuals as controls or MCI and as a result, these studies create 
models that identify subjects correctly 60-81% of the time, and solely examine the 
discriminatory value of one region of the brain (Hanseeuw et al., 2011; Mueller et al., 
2010; Pennanen et al., 2004). Therefore, some studies are attempting to include multiple 
ROI volumes in their models to achieve higher classification rates (Colliot et al., 1997; 
Colliot et al., 2000; Hangii et al., 2011; Killiany et al., 2001).  
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Initially, the present study utilized hippocampal volume, hippocampal subfield 
volumes, and entorhinal cortex volume to build three separate classification models and 
individually, these ROI subgroups performed poorly at classification. However, when 
other cortical ROIs were added to the classification model, we were able to correctly 
identify 44 out of 46 control participants and 48 out of 50 MCI participants for an overall 
classification accuracy of 95.83% with 96% sensitivity and 95.65% specificity.  Table 3 
shows the 11 volumes that contributed most to this model. Notably, additional cortical 
regions beyond the canonical medial temporal regions were added to our model in order 
to see which other structures contribute to identification outside those most commonly 
studied.  
Interestingly, the present study found both whole left hippocampal formation and 
right subiculum volume to be significant predictors (p’s = 0.00281) in our model. 
However, similar cross-sectional studies comparing the discriminatory value of 
hippocampal subfields versus whole hippocampal volumes have found single subfields 
often better differentiate between control and MCI groups (Hanseeuw et al., 2011; LaJoie 
et al., 2013, Pluta et al., 2012). Hanseeuw and colleagues (2011) found the subiculum to 
be a more effective predictor than the whole hippocampus and both La Joie et al. and 
Pluta et al. found the CA1 to be a stronger predictor than whole hippocampal volume. 
Regardless, the present study found the left whole hippocampal volume to be selected 
into the final stepwise variable logistic model while neither the right nor the left CA1 
were selected. 
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Thus far, less research has been done analyzing the influence of cortical structures 
in classification models for control and MCI populations. However, a three-year study by 
Killiany and colleagues (2001) found the baseline volume of the caudal portion of the 
anterior cingulate to be one of the top three predictors for discriminating control subjects, 
subjects who maintained stable mild cognitive impairment during the duration of the 
study, and subjects that converted to AD from MCI by the end of the three-year period. In 
the present study, we also found the caudal portion of the right anterior cingulate (p = 
0.00281) to be one of the 11 selected predictors for group membership. Similarly, a study 
conducted by Hängii and colleagues (2011) found the left superior parietal gyrus to 
achieve high diagnostic accuracy in identifying controls versus MCI subjects. The present 
study also found the left superior parietal cortex to be a significant predictor in the 
classification model (p = 0.00003). 
A cross-sectional study conducted by Convit and colleagues (1997) initially built 
a model that attempted to classify controls and MCI subjects solely based on 
hippocampal volume and obtained a classification accuracy of 73.4% (Convit et al., 
1997). The addition of temporal lobe regions did not improve classification between 
these two groups, however, future studies conducted by Convit and colleagues continued 
to include less-studied regions of the temporal lobe into their models. Three years later, 
Convit and colleagues (2000) found that adding the fusiform gyrus and combined middle 
and inferior temporal gyrus improved classification rates in identifying who with MCI 
would further decline to AD (Convit et al., 2000). Notably, the present study also found 
the right middle temporal gyrus (p = 0.00059) to be a significant predictor in group 
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membership and the left fusiform gyrus approached significance (p = 0.0435). While it 
should be noted that these studies investigated group membership of differing cognitive 
capacities, the overlapping ROIs of significance in both studies may suggest some 
implications of the middle temporal gyri and the fusiform gyri in the progression of 
cognitive impairment.   
Aside from creating classification models, other studies focus on identifying 
regions that show the greatest amount of volume loss in MCI subjects compared to 
controls. In many of these studies, researchers point to regions such as the parietal and 
lateral temporal lobes as among the first to be implicated in the early stages of AD along 
with the medial temporal lobe (Desikan et al., 2009; Fan et al., 2008). Interestingly, these 
studies discuss volume reductions in many of the regions that were chosen to be 
significant predictors in our classification model. Such include the left insula (p = 
0.0003), left superior parietal cortex (p = 0.0003), right middle temporal cortex (p = 
0.00059), and right paracentral lobule (p = 0.00086). For example, studies by both Fan 
and colleagues (2008) as well as Karas and colleagues (2004) reported the insula to be 
one of the most affected structures in MCI subjects compared to controls. Likewise, the 
middle temporal gyrus was also reported to have greater atrophy in MCI subjects 
compared to controls in the study conducted by Fan and colleagues (2008). Therefore, 
while these studies do not attempt to make classification models like the present study, 
the reoccurring significance of regions such as the insula and middle temporal cortex may 
suggest such regions have some role in the progression of cognitive impairment and 
disease. Further research creating classification models of control and MCI subjects 
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utilizing both medial temporal regions as well as less-studied cortical regions will likely 
help clarify which regions in the present study model are truly predictors of cognitive 
impairment versus characteristics of this particular sample. Additionally, it should be 
noted that of the 50 amnestic MCI subjects used in this study, 42 were amnestic in a 
single domain while 8 were amnestic in multiple domains such as memory and language, 
executive function, visuospatial functioning or a combination of these skills. It is possible 
the utilization of these eight participants could have influenced the findings of this study. 
Therefore, future studies creating similar classification models should aim to use solely 
single domain amnestic subjects to help solidify whether the 11 significant regions 
reported in this study are true predictors or if these findings reflect a characteristic of this 
sample. 
Limitations 
While the best fit model created in this study is promising, there are limitations 
that must be considered.  This study utilized sufficient data to meet the intended goals, 
but the sample size is nonetheless modest. This was driven by a desire to make optimal 
use of MCI and control participants from our local ADC population as it more closely 
resembles a clinical population. We supplemented the subject number using participants 
from the ADNI study, though we did not want to overwhelm the study with the “clinical 
trials population” found in ADNI (Petersen et al., 2013). Furthermore, when working 
with classification models such as nominal logistic regression, the ultimate goal is to 
build a model using one dataset and then apply it to a parallel dataset. Since we aimed to 
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investigate regions that are less-studied in MCI, we used all our available subjects to 
build the model. As such, we realize the potential to be able to refine our findings in a 
future study as more local participants become available. 
Conclusion 
The results of the present study confirm many previous findings regarding 
reduced volume in the hippocampus, entorhinal cortex, and hippocampal subfields in 
MCI subjects when compared to controls. Additionally, our findings provide further 
evidence of the value of less-studied regions outside the medial temporal lobe and their 
ability to aid discrimination models of those who exhibit normal aging and those who do 
not. We anticipate that future work will continue analyzing which cortical measures in 
combination with whole hippocampal, hippocampal subfields, and entorhinal cortex 
volumes contribute most to classification models of group membership. This can provide 
a basis for assessing disease progression and efficacy of potential therapeutic 
interventions. Additionally, future studies will likely need to include PET and CSF 
measures of amyloid and tau along with MRI measures in their statistical models in order 
to continue improving such models. 
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APPENDIX 
Cortical Volumes (68 total, 34 per hemisphere): 
 
Right Banks of the Superior Temporal Sulcus 
Right Caudal Anterior Cingulate 
Right Caudal Middle Frontal 
Right Cuneus 
Right Entorhinal  
Right Fusiform 
Right Inferior Parietal 
Right Inferior Temporal 
Right Isthmus Cingulate 
Right Lateral Occipital 
Right Lateral Orbitofrontal 
Right Lingual 
Right Medial Orbitofrontal 
Right Middle Temporal 
Right Parahippocampal 
Right Paracentral 
Right Pars Opercularis 
Right Pars Orbitalis 
Right Pars Triangularis 
Right Pericalcarine 
Right Postcentral 
Right Posterior Cingulate 
Right Precentral 
Right Precuneus 
Right Rostral Anterior Cingulate 
Right Rostral Middle Frontal 
Right Superior Frontal 
Right Superior Parietal 
Right Superior Temporal 
Right Supramarginal 
Right Frontal Pole 
Right Temporal Pole 
Right Transverse Temporal 
Right Insula 
Left Banks of the Superior Temporal Sulcus 
Left Caudal Anterior Cingulate 
Left Caudal Middle Frontal 
Left Cuneus 
Left Entorhinal  
Left Fusiform 
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Left Inferior Parietal 
Left Inferior Temporal 
Left Isthmus Cingulate 
Left Lateral Occipital 
Left Lateral Orbitofrontal 
Left Lingual 
Left Medial Orbitofrontal 
Left Middle Temporal 
Left Parahippocampal 
Left Paracentral 
Left Pars Opercularis 
Left Pars Orbitalis 
Left Pars Triangularis 
Left Pericalcarine 
Left Postcentral 
Left Posterior Cingulate 
Left Precentral 
Left Precuneus 
Left Rostral Anterior Cingulate 
Left Rostral Middle Frontal 
Left Superior Frontal 
Left Superior Parietal 
Left Superior Temporal 
Left Supramarginal 
Left Frontal Pole 
Left Temporal Pole 
Left Transverse Temporal 
Left Insula 
 
Subcortical Volumes (12 total, 6 per hemisphere): 
 
Total Left Lateral Ventricle 
Left Thalamus 
Left Caudate 
Left Putamen 
Left Pallidum 
Left Amygdala 
Total Right Lateral Ventricle 
Right Thalamus 
Right Caudate 
Right Putamen 
Right Pallidum 
Right Amygdala 
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Hippocampal Formation (2 total, 1 per hemisphere) and Hippocampal Subfields (24 total, 
12 per hemisphere): 
 
Right Hippocampus 
Left Hippocampus 
Left Hippocampal Tail 
Left Subiculum 
Left CA1 
Left Hippocampal Fissure 
Left Presubiculum 
Left Parasubiculum 
Left Molecular Layer 
Left Dentate Gyrus 
Left CA3 
Left CA4 
Left Fimbria 
Left Hippocampal Amygdala Transition Area 
Right Hippocampal Tail 
Right Subiculum 
Right CA1 
Right Hippocampal Fissure 
Right Presubiculum 
Right Parasubiculum 
Right Molecular Layer 
Right Dentate Gyrus 
Right CA3 
Right CA4 
Right Fimbria 
Right Hippocampal Amygdala Transition Area 
 
 
Other (3): 
 
Estimated Intracranial Volume (eTIV) 
3rd Ventricle 
4th Ventricle 
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